Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

AI Voice Calls Versus Text and Email Reminders for Questionnaire Response After Shoulder Arthroplasty (VOICE-REACH)

10 de novembro de 2026 atualizado por: Institut de Chirurgie Reparatrice Locomoteur et Sports

Proactive Conversational Artificial Intelligence Calls Versus Digital Reminders to Collect Patient-Reported Outcomes After Shoulder Arthroplasty: A Randomized Study Within a Multicenter Cohort

After shoulder replacement surgery, surgeons send questionnaires to their patients to learn how they are doing (pain, shoulder function, satisfaction). Many patients do not answer. This study tests the best way to obtain these answers.

The study is nested in a multicenter study of pain after shoulder arthroplasty conducted in four French centers (host study RetroPAinRSACAll, supported by Ramsay Santé). The clinical results of the host study are not the subject of this registration: this study evaluates only the method used to collect the information.

All patients first receive an email invitation (when an email address is available) and, the next day, a text message (SMS) with a personal link to the questionnaire and a phone number to answer at any time by talking with an automated voice assistant. Patients who have not answered two days after the first contact are randomly assigned to one of two follow-up strategies: (1) further digital reminders (SMS on day 3 and day 5, email on day 7), or (2) up to three phone calls from a conversational artificial intelligence (AI) voice agent on days 3, 5 and 7, which asks the same questions orally. In both groups, patients can answer at any time online or by calling the voice assistant, and contacts stop as soon as the questionnaire is completed or the patient refuses.

The main outcome is the proportion of patients who complete the questionnaire within 14 days of the first contact.

Visão geral do estudo

Descrição detalhada

Design. VOICE-REACH is a pragmatic, multicenter, individually randomized, two-arm, open-label superiority study within a trial (SWAT). It is embedded in the host study RetroPAinRSACAll (persistent pain after shoulder arthroplasty, four French shoulder surgery centers, favorable opinion of the Ramsay Santé scientific committee, reference COS-RGDS-2026-07-008). All patients of the host cohort are contacted through the DeepCall platform on behalf of their surgeon to complete the host study questionnaire (operation details, warning signs, pain screening and characterization, rehabilitation and function including the Subjective Shoulder Value, opinion on the operation and on the contact). The comparison concerns the follow-up strategy only: the questionnaire is the same in both arms and the same on the web and by voice.

Common phase (all participants). Day 0: email invitation with a personal questionnaire link, sent when an email address is available. Day 1: SMS with the same link, the phone number of the AI voice agent (available 24 hours a day for inbound calls) and an opt-out option (reply NO). Patients are contacted in successive waves of up to 450 patients, one day apart, to respect operator sending limits; all study days are counted from each participant's own day 0.

Randomization. On day 2, participants who have not completed the questionnaire and have not refused are randomized 1:1 by the platform, using a computer-generated permuted block sequence (blocks of 4) stratified by center. Participants who completed the questionnaire before day 2 are not randomized and are described separately.

Arm A, digital reminders: SMS reminders on day 3 and day 5 and an email reminder on day 7 (when an email address is available).

Arm B, proactive AI calls: outbound calls from the AI voice agent on day 3, day 5 and day 7 (up to three attempts). The agent calls on behalf of the surgeon's team and asks the questionnaire orally; answers are extracted into the same structured fields as the web form.

In both arms, the web link and the inbound voice line remain available throughout, and all scheduled contacts stop as soon as the questionnaire is completed, the patient refuses, or the patient is identified as deceased. Warning signs reported by patients are flagged to the surgical team for review; the AI agent does not give medical advice.

Analysis. The primary analysis is intention to treat among all randomized participants: proportion with a completed questionnaire by day 14, risk difference (Arm B minus Arm A) with 95% confidence interval, adjusted for center and email availability. Participants without a completed questionnaire by day 14 are counted as non-completers; no answer is imputed. Secondary analyses describe the yield of the common phase, time to completion, completion channel, partial responses, refusals, number of contacts and cost per completed questionnaire, acceptability of the contact mode among responders, representativeness of responders, and the accuracy of voice-captured answers.

Registration timing. The common pre-randomization outreach started on 9 November 2026. This record was created on 10 November 2026, before the first randomization (day 2 of the first wave, 11 November 2026).

Tipo de estudo

Intervencional

Inscrição (Estimado)

846

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Caen, França, 14000
        • Recrutamento
        • Hôpital Privé Saint-Martin
        • Investigador principal:
          • Franck Dordain, MD
      • Lyon, França, 69008
        • Recrutamento
        • Centre Orthopédique Santy, Hôpital Privé Jean Mermoz
        • Investigador principal:
          • Arnaud Godenèche, MD
      • Paris, França, 75019
        • Recrutamento
        • Clinique des Maussins-Nollet
        • Investigador principal:
          • Geoffroy Nourissat, MD, PhD
      • Strasbourg, França, 67000
        • Recrutamento
        • Clinique de l'Orangerie
        • Investigador principal:
          • Maxime Antoni, MD

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age 18 years or older
  • Shoulder arthroplasty (reverse, anatomic, humeral head replacement or revision arthroplasty) performed at one of the four participating centers and listed in the host study cohort
  • At least one telephone number available (an email address is not required)

Additional criteria for randomization (day 2):

* Questionnaire not completed and no refusal at the day-2 cutoff

Exclusion Criteria:

  • Death identified before the first contact (cross-check with the French national death registry, INSEE)
  • Duplicate record
  • Refusal of contact
  • Questionnaire already completed before day 2 (excluded from randomization only, described separately)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Pesquisa de serviços de saúde
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Digital Reminders

Common phase: email invitation on day 0 (if an email address is available) and SMS invitation on day 1 with the questionnaire link and the AI voice agent phone number. After randomization on day 2: SMS reminder on day 3, SMS reminder on day 5 and email reminder on day 7 (if an email address is available). Participants can answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal.

Standardized reminder messages sent by the DeepCall platform on behalf of the surgeon: SMS on day 3 and day 5 and email on day 7 (if an email address is available), each with the personal questionnaire link, the AI voice agent phone number and an opt-out option.

Experimental: Proactive AI Voice Calls

Same common phase (email on day 0 if available, SMS on day 1). After randomization on day 2: up to three outbound calls from the conversational AI voice agent on day 3, day 5 and day 7, during which the same questionnaire is asked orally. Participants can also answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal.

Outbound telephone calls placed by a conversational AI voice agent (DeepCall platform) on day 3, day 5 and day 7, up to three attempts. The agent calls on behalf of the surgeon's team, conducts the same questionnaire orally and records the answers in the same structured fields as the web form.

Outros nomes:
  • DeepCall

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Questionnaire Completion by Day 14 Among Randomized Participants
Prazo: From day 0 (first contact) to day 14

Proportion of randomized participants with a completed questionnaire within 14 days of their first contact (day 0), whatever the channel used (web link, inbound call or outbound AI call). A questionnaire is complete when it was submitted on the web or when all required items were answered during a voice interview. Participants without a completed questionnaire at the day-14 cutoff are counted as non-completers. Compared between arms (proactive AI voice calls minus digital reminders).

From day 0 (first contact) to day 14

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Questionnaire Completion by Day 7 Among Randomized Participants
Prazo: From day 0 to day 7

Proportion of randomized participants with a completed questionnaire by day 7, whatever the channel used.

From day 0 to day 7
Time to Questionnaire Completion
Prazo: From day 2 to day 14

Time in hours from randomization (day 2) to questionnaire completion among randomized participants; participants without a completed questionnaire are censored at day 14.

From day 2 to day 14
Questionnaire Completion Before Randomization
Prazo: From day 0 to day 2

Proportion of all enrolled participants who completed the questionnaire after the common email (day 0) and SMS (day 1) invitations, before the day-2 randomization.

From day 0 to day 2
Questionnaire Completion by Day 14 in All Enrolled Participants
Prazo: From day 0 to day 14

Proportion of all enrolled participants, randomized or not, with a completed questionnaire by day 14.

From day 0 to day 14
Partial Questionnaire Response
Prazo: From day 0 to day 14

Proportion of randomized participants who answered at least one question without completing the questionnaire by day 14.

From day 0 to day 14
Completion Channel
Prazo: From day 0 to day 14

Distribution of completed questionnaires by channel (web link, inbound call to the voice agent, outbound AI call), by arm.

From day 0 to day 14
Refusal of Contact
Prazo: From day 2 to day 14

Proportion of randomized participants who explicitly refused further contact (SMS reply, email refusal link or refusal during a call).

From day 2 to day 14
Number of Contacts per Completed Questionnaire
Prazo: From day 0 to day 14

Number of emails, SMS and outbound calls sent or attempted, divided by the number of completed questionnaires, by arm.

From day 0 to day 14
Direct Cost per Completed Questionnaire
Prazo: From day 0 to day 14

Direct costs of messaging, telephony and AI processing (euros) divided by the number of completed questionnaires, by arm, and incremental cost per additional completed questionnaire.

From day 0 to day 14
Satisfaction With the Mode of Contact
Prazo: From day 0 to day 14

Among participants who completed the questionnaire: satisfaction with the way they were contacted, rated on a 5-level scale from very satisfied to very dissatisfied.

From day 0 to day 14
Perceived Number of Contacts
Prazo: From day 0 to day 14

Among participants who completed the questionnaire: perceived number of contacts (too many, appropriate, too few).

From day 0 to day 14
Preferred Contact Mode for Future Follow-up
Prazo: From day 0 to day 14

Among participants who completed the questionnaire: preferred mode of contact for future follow-up questionnaires (categorical).

From day 0 to day 14
Characteristics of Responders Versus Non-Responders
Prazo: Day 14

Age, center, type of arthroplasty and time since surgery (when available in the host cohort) compared between participants who completed the questionnaire and those who did not, by arm (standardized differences).

Day 14
Agreement Between Voice-Captured Answers and Human Review
Prazo: From day 0 to day 14

In a random sample of completed voice interviews, agreement between the answers extracted by the AI agent and those coded by a reviewer listening to the recording, blinded to the extracted values (percentage agreement, kappa or intraclass correlation coefficient).

From day 0 to day 14

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Delivery of Email and SMS Invitations
Prazo: From day 0 to day 7

Proportion of emails and SMS delivered, bounced or filtered by the operator, as reported by the sending providers.

From day 0 to day 7
Outbound Call Outcomes
Prazo: From day 3 to day 7

Distribution of outbound AI call outcomes (answered, voicemail, no answer, filtered, failed) and call duration in the proactive AI voice calls arm.

From day 3 to day 7

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Jules Descamps, MD, MSc, Hopital Lariboisière
  • Cadeira de estudo: Geoffroy Nourissat, MD, PhD, Clinique des Maussins-Nollet, Ramsay Santé

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

9 de novembro de 2026

Conclusão Primária (Estimado)

24 de novembro de 2026

Conclusão do estudo (Estimado)

24 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

10 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Identifiable data, call recordings and transcripts will not be shared. Aggregated results will be published.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever